Device manufacturer Berry Global says that it intends to hire 500 employees over 8 years to staff its new manufacturing facility in Bangalore, India, which will produce a variety of products, including nasal and inhaled drug delivery devices. The company had announced plans for the site in August 2021. Berry says that the Bangalore site has received International Sustainability and Carbon Certificate (ISCC) Plus designation, and about 90% of the power for the site will be solar and wind power.
According to Berry, the production facility could begin operations as soon as April of this year. In addition to the new manufacturing plant, a new R&D Center of Excellence will also open on the site, and the company noted that the R&D center is expected to launch new inhalation products this year, including a breath-actuated multidose inhaler.
Berry Global Chairman and CEO Tom Salmon commented, “Healthcare companies have limited access to regional expertise and global capabilities needed to provide patient populations in Asia with modern healthcare solutions at scale. Our new facility and global healthcare center of excellence in Bangalore will support Asia’s growing demand for healthcare products, create new jobs, and, most importantly, benefit the lives of patient populations who have historically gone untreated and underdiagnosed.”
Berry President of Consumer Packaging International Jean-Marc Galvez said, “Improved drug affordability and greater access to modern healthcare solutions are more important than ever in India, one of the most populated countries in the world. Our new facility and R&D center will benefit the domestic economy by creating new jobs and the regional economy overall by improving healthcare access and providing locally manufactured products.”
Read the Berry Global press release.
